- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06357533
PD-L1 발현이 높고(TC ≥ 50%) 실행 가능한 게놈 변형이 없는 진행성 비편평 NSCLC에 대한 Rilvegostomig와 병용한 1차 Dato-DXd에 대한 공개 라벨 제3상 연구 (TROPION-Lung10)
높은 국소 진행성 또는 전이성 비편평 NSCLC 참가자의 1차 치료를 위한 릴베고스토미그 또는 릴베고스토미그 단독요법과 펨브롤리주맙 단독요법과의 병용 다토포타맙 데룩스테칸(Dato-DXd)에 대한 제3상 무작위 공개 라벨 글로벌 연구 PD-L1 발현(TC ≥ 50%) 및 실행 가능한 게놈 변경 없음(TROPION-Lung10)
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.
연구 개요
상세 설명
This is a Phase III, randomized, open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig monotherapy compared with Pembrolizumab monotherapy for the first-line treatment of participants with locally-advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: AstraZeneca Clinical Study Information Center
- 전화번호: 1-877-240-9479
- 이메일: information.center@astrazeneca.com
연구 장소
-
-
-
Changhua, 대만, 500
- 아직 모집하지 않음
- Research Site
-
Kaohsiung City, 대만, 80756
- 모병
- Research Site
-
New Taipei City, 대만, 220
- 모병
- Research Site
-
Taichung, 대만, 40447
- 모병
- Research Site
-
Taichung, 대만, 40705
- 모병
- Research Site
-
Tainan, 대만, 704
- 모병
- Research Site
-
Taipei, 대만, TAIWAN
- 모병
- Research Site
-
Taipei, 대만, 10002
- 모병
- Research Site
-
Taipei, 대만, 112
- 모병
- Research Site
-
Taipei, 대만, 0116
- 모병
- Research Site
-
Taoyuan, 대만, 333
- 모병
- Research Site
-
-
-
-
-
Changwon, 대한민국, 51353
- 모병
- Research Site
-
Incheon, 대한민국, 21565
- 모병
- Research Site
-
Seongnam-si, 대한민국, 13496
- 모병
- Research Site
-
Seoul, 대한민국, 03080
- 모병
- Research Site
-
Seoul, 대한민국, 03722
- 모병
- Research Site
-
Seoul, 대한민국, 08308
- 아직 모집하지 않음
- Research Site
-
Seoul, 대한민국, 06973
- 모병
- Research Site
-
Suwon, 대한민국, 16247
- 모병
- Research Site
-
Suwon, 대한민국, 16499
- 모병
- Research Site
-
-
-
-
-
Berlin, 독일, 10249
- 아직 모집하지 않음
- Research Site
-
Bonn, 독일, 53113
- 모병
- Research Site
-
Cologne, 독일, 50677
- 모병
- Research Site
-
Düsseldorf, 독일, 40489
- 빼는
- Research Site
-
Essen, 독일, 45136
- 모병
- Research Site
-
Freiburg im Breisgau, 독일, 79106
- 모병
- Research Site
-
Gauting, 독일, 82131
- 모병
- Research Site
-
Georgsmarienhütte, 독일, 49124
- 빼는
- Research Site
-
Gera, 독일, 07548
- 빼는
- Research Site
-
Gütersloh, 독일, 33332
- 빼는
- Research Site
-
Hamburg, 독일, 20251
- 모병
- Research Site
-
Hamburg, 독일, 22087
- 모병
- Research Site
-
Heidelberg, 독일, 69126
- 모병
- Research Site
-
Kempten, 독일, 87439
- 정지된
- Research Site
-
Kiel, 독일, 24116
- 아직 모집하지 않음
- Research Site
-
Koblenz, 독일, 56068
- 정지된
- Research Site
-
Ludwigsburg, 독일, 71640
- 빼는
- Research Site
-
München, 독일, 81925
- 모병
- Research Site
-
Nuremberg, 독일, 90419
- 빼는
- Research Site
-
Potsdam, 독일, 14467
- 모병
- Research Site
-
Ravensburg, 독일, 88212
- 모병
- Research Site
-
-
-
-
Alaska
-
Anchorage, Alaska, 미국, 99508
- 모병
- Research Site
-
-
Arizona
-
Tucson, Arizona, 미국, 85719
- 모병
- Research Site
-
-
Arkansas
-
Little Rock, Arkansas, 미국, 72205
- 모병
- Research Site
-
Springdale, Arkansas, 미국, 72762
- 모병
- Research Site
-
-
California
-
Anaheim, California, 미국, 92801
- 모병
- Research Site
-
Beverly Hills, California, 미국, 90211
- 모병
- Research Site
-
Fountain Valley, California, 미국, 92708
- 모병
- Research Site
-
Newport Beach, California, 미국, 92663
- 정지된
- Research Site
-
-
Florida
-
Clermont, Florida, 미국, 34711
- 모병
- Research Site
-
Gainesville, Florida, 미국, 32608
- 모병
- Research Site
-
Miami Beach, Florida, 미국, 33140
- 모병
- Research Site
-
Orange City, Florida, 미국, 32763
- 모병
- Research Site
-
Orlando, Florida, 미국, 32806
- 모병
- Research Site
-
Orlando, Florida, 미국, 32827
- 빼는
- Research Site
-
West Palm Beach, Florida, 미국, 33401
- 모병
- Research Site
-
-
Georgia
-
Atlanta, Georgia, 미국, 30322
- 모병
- Research Site
-
Atlanta, Georgia, 미국, 30318
- 모병
- Research Site
-
Atlanta, Georgia, 미국, 30342
- 빼는
- Research Site
-
Atlanta, Georgia, 미국, 30303
- 정지된
- Research Site
-
-
Illinois
-
Hinsdale, Illinois, 미국, 60521
- 모병
- Research Site
-
-
Indiana
-
Noblesville, Indiana, 미국, 46062
- 모병
- Research Site
-
-
Kentucky
-
Paducah, Kentucky, 미국, 42003
- 모병
- Research Site
-
-
Maryland
-
Annapolis, Maryland, 미국, 21401
- 모병
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02215
- 모병
- Research Site
-
Boston, Massachusetts, 미국, 02114
- 모병
- Research Site
-
-
Michigan
-
Dearborn, Michigan, 미국, 48126
- 모병
- Research Site
-
Farmington Hills, Michigan, 미국, 48334
- 모병
- Research Site
-
Grand Rapids, Michigan, 미국, 49503
- 모병
- Research Site
-
Traverse City, Michigan, 미국, 49684
- 빼는
- Research Site
-
-
Mississippi
-
Hattiesburg, Mississippi, 미국, 39401
- 모병
- Research Site
-
-
Missouri
-
Kansas City, Missouri, 미국, 64132
- 모병
- Research Site
-
-
Montana
-
Bozeman, Montana, 미국, 59715
- 빼는
- Research Site
-
-
Nebraska
-
Grand Island, Nebraska, 미국, 68803
- 모병
- Research Site
-
Omaha, Nebraska, 미국, 68130
- 모병
- Research Site
-
-
Nevada
-
Las Vegas, Nevada, 미국, 89102
- 모병
- Research Site
-
Reno, Nevada, 미국, 89502
- 빼는
- Research Site
-
-
New Jersey
-
Voorhees Township, New Jersey, 미국, 08043
- 정지된
- Research Site
-
-
New York
-
Stony Brook, New York, 미국, 11794
- 모병
- Research Site
-
-
North Carolina
-
Greenville, North Carolina, 미국, 27834
- 모병
- Research Site
-
Salisbury, North Carolina, 미국, 28144
- 모병
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45219
- 모병
- Research Site
-
Columbus, Ohio, 미국, 43210
- 빼는
- Research Site
-
Maumee, Ohio, 미국, 43537
- 모병
- Research Site
-
Toledo, Ohio, 미국, 43623
- 모병
- Research Site
-
-
Oregon
-
Portland, Oregon, 미국, 97213
- 빼는
- Research Site
-
-
South Carolina
-
Greenville, South Carolina, 미국, 29607
- 모병
- Research Site
-
-
South Dakota
-
Sioux Falls, South Dakota, 미국, 57105
- 모병
- Research Site
-
-
Tennessee
-
Chattanooga, Tennessee, 미국, 37404
- 빼는
- Research Site
-
Knoxville, Tennessee, 미국, 37920
- 빼는
- Research Site
-
-
Texas
-
Fort Worth, Texas, 미국, 76104
- 모병
- Research Site
-
Houston, Texas, 미국, 77030
- 모병
- Research Site
-
Houston, Texas, 미국, 77030
- 빼는
- Research Site
-
Houston, Texas, 미국, 77090
- 정지된
- Research Site
-
Kingwood, Texas, 미국, 77339
- 모병
- Research Site
-
Odessa, Texas, 미국, 79761
- 모병
- Research Site
-
-
Virginia
-
Fort Belvoir, Virginia, 미국, 22060
- 모병
- Research Site
-
Leesburg, Virginia, 미국, 20176
- 모병
- Research Site
-
Midlothian, Virginia, 미국, 23114
- 모병
- Research Site
-
Richmond, Virginia, 미국, 23230
- 모병
- Research Site
-
-
Washington
-
Tacoma, Washington, 미국, 98405
- 모병
- Research Site
-
Vancouver, Washington, 미국, 98684
- 모병
- Research Site
-
Wenatchee, Washington, 미국, 98801
- 모병
- Research Site
-
-
Wisconsin
-
Appleton, Wisconsin, 미국, 54911
- 모병
- Research Site
-
-
-
-
-
Da Nang, 베트남, 550000
- 모병
- Research Site
-
Hanoi, 베트남, 100000
- 모병
- Research Site
-
Ho Chi Minh City, 베트남, 700000
- 모병
- Research Site
-
Ho Chi Minh City, 베트남, 700000
- 빼는
- Research Site
-
Huế, 베트남, 530000
- 빼는
- Research Site
-
Hà Nội, 베트남, 100000
- 모병
- Research Site
-
Vinh, 베트남, 460000
- 빼는
- Research Site
-
Vĩnh Yên, 베트남, 280000
- 모병
- Research Site
-
-
-
-
-
Anderlecht, 벨기에, 1070
- 빼는
- Research Site
-
Bruges, 벨기에, 8000
- 모병
- Research Site
-
Hasselt, 벨기에, 3500
- 모병
- Research Site
-
La Louvière, 벨기에, 7100
- 모병
- Research Site
-
Liège, 벨기에, 4000
- 모병
- Research Site
-
-
-
-
-
Barretos, 브라질, 14784-400
- 모병
- Research Site
-
Curitiba, 브라질, 80730-150
- 모병
- Research Site
-
Florianópolis, 브라질, 88034-000
- 모병
- Research Site
-
Ipatinga, 브라질, 35162-189
- 모병
- Research Site
-
Natal, 브라질, 59075-740
- 모병
- Research Site
-
Porto Alegre, 브라질, 91350-200
- 모병
- Research Site
-
Rio de Janeiro, 브라질, 22211-230
- 모병
- Research Site
-
Santa Maria, 브라질, 97015-450
- 모병
- Research Site
-
São Paulo, 브라질, 01221-020
- 모병
- Research Site
-
Taubaté, 브라질, 12030-200
- 모병
- Research Site
-
-
-
-
-
Alicante, 스페인, 03010
- 모병
- Research Site
-
Barcelona, 스페인, 08036
- 모병
- Research Site
-
Barcelona, 스페인, 08003
- 모병
- Research Site
-
Barcelona, 스페인, 08041
- 아직 모집하지 않음
- Research Site
-
Jerez de la Frontera, 스페인, 11407
- 모병
- Research Site
-
Reus, 스페인, 43204
- 모병
- Research Site
-
Salamanca, 스페인, 37007
- 빼는
- Research Site
-
-
-
-
-
Cheltenham, 영국, GL53 7AN
- 정지된
- Research Site
-
Inverness, 영국, IV2 3UJ
- 정지된
- Research Site
-
London, 영국, SW17 0QT
- 모병
- Research Site
-
London, 영국, SW10 9NH
- 모병
- Research Site
-
London, 영국, SE1 9RT
- 빼는
- Research Site
-
Norwich, 영국, NR4 7UY
- 모병
- Research Site
-
Preston, 영국, PR2 9HT
- 모병
- Research Site
-
Truro, 영국, TR1 3LJ
- 모병
- Research Site
-
-
-
-
-
Innsbruck, 오스트리아, 6020
- 모병
- Research Site
-
Krems, 오스트리아, 3500
- 모병
- Research Site
-
Linz, 오스트리아, 4020
- 모병
- Research Site
-
Rankweil, 오스트리아, 6830
- 모병
- Research Site
-
Vienna, 오스트리아, 1210
- 모병
- Research Site
-
Vienna, 오스트리아, 1140
- 모병
- Research Site
-
Wels, 오스트리아, 4600
- 빼는
- Research Site
-
-
-
-
-
Bergamo, 이탈리아, 24125
- 모병
- Research Site
-
Genoa, 이탈리아, 16132
- 모병
- Research Site
-
Milan, 이탈리아, 20141
- 모병
- Research Site
-
Milan, 이탈리아, 20162
- 모병
- Research Site
-
Monza, 이탈리아, 20052
- 모병
- Research Site
-
Padova, 이탈리아, 35128
- 모병
- Research Site
-
Pavia, 이탈리아, 27100
- 모병
- Research Site
-
Ravenna, 이탈리아, 48100
- 모병
- Research Site
-
Roma, 이탈리아, 00128
- 모병
- Research Site
-
Rozzano, 이탈리아, 20089
- 모병
- Research Site
-
-
-
-
-
Chennai, 인도, 600031
- 모병
- Research Site
-
Dwārka, 인도, 110075
- 모병
- Research Site
-
Jaipur, 인도, 302004
- 모병
- Research Site
-
Kolkata, 인도, 700099
- 모병
- Research Site
-
Marg Jaipur, 인도, 302004
- 빼는
- Research Site
-
Nagpur, 인도, 440001
- 모병
- Research Site
-
Nashik, 인도, 422011
- 모병
- Research Site
-
New Delhi, 인도, 11029
- 모병
- Research Site
-
New Delhi, 인도, 110085
- 모병
- Research Site
-
Surat, 인도, 395002
- 모병
- Research Site
-
Thiruvananthapuram, 인도, 695011
- 빼는
- Research Site
-
-
-
-
-
Bunkyō City, 일본, 113-8431
- 모병
- Research Site
-
Bunkyō City, 일본, 160-0023
- 모병
- Research Site
-
Fukuoka, 일본, 812-8582
- 모병
- Research Site
-
Fukuoka, 일본, 814-0180
- 모병
- Research Site
-
Hakodate-shi, 일본, 040-8611
- 모병
- Research Site
-
Hidaka-shi, 일본, 350-1298
- 모병
- Research Site
-
Hirakata-shi, 일본, 573-1191
- 모병
- Research Site
-
Hirosaki-shi, 일본, 036-8563
- 모병
- Research Site
-
Hiroshima, 일본, 730-8518
- 모병
- Research Site
-
Kanazawa, 일본, 920-8641
- 모병
- Research Site
-
Kashiwa, 일본, 227-8577
- 모병
- Research Site
-
Kawasaki-shi, 일본, 216-8511
- 모병
- Research Site
-
Kumamoto, 일본, 860-8556
- 모병
- Research Site
-
Matsusaka-shi, 일본, 515-8544
- 모병
- Research Site
-
Matsuyama, 일본, 790-0024
- 모병
- Research Site
-
Nagoya, 일본, 460-0001
- 모병
- Research Site
-
Niigata, 일본, 951-8566
- 모병
- Research Site
-
Okayama, 일본, 700-8558
- 모병
- Research Site
-
Osaka, 일본, 545-8586
- 빼는
- Research Site
-
Osakasayama-shi, 일본, 589-8511
- 모병
- Research Site
-
Sagamihara-shi, 일본, 252-0375
- 모병
- Research Site
-
Sapporo, 일본, 003-0804
- 모병
- Research Site
-
Takaoka-shi, 일본, 933-8555
- 모병
- Research Site
-
Takatsuki-shi, 일본, 569-8686
- 모병
- Research Site
-
Tokushima, 일본, 770-8503
- 모병
- Research Site
-
Tokyo, 일본, 104-0045
- 모병
- Research Site
-
Utsunomiya, 일본, 320-0834
- 모병
- Research Site
-
Yokohama, 일본, 221-0855
- 모병
- Research Site
-
-
-
-
-
Beijing, 중국, 100142
- 모병
- Research Site
-
Beijing, 중국, 101149
- 모병
- Research Site
-
Changchun, 중국, 130000
- 모병
- Research Site
-
Changsha, 중국, 410013
- 모병
- Research Site
-
Chengdu, 중국, 610000
- 모병
- Research Site
-
Chengdu, 중국, 610041
- 모병
- Research Site
-
Chongqing, 중국, 400030
- 모병
- Research Site
-
Fuzhou, 중국, 350014
- 모병
- Research Site
-
Guangzhou, 중국, 510080
- 모병
- Research Site
-
Hangzhou, 중국, 310006
- 모병
- Research Site
-
Hangzhou, 중국, 310022
- 모병
- Research Site
-
Hangzhou, 중국, 310016
- 모병
- Research Site
-
Harbin, 중국, 150049
- 모병
- Research Site
-
Hefei, 중국, 230601
- 모병
- Research Site
-
Hefei, 중국, 230031
- 빼는
- Research Site
-
Jinan, 중국, 250117
- 모병
- Research Site
-
Jining, 중국, 272011
- 빼는
- Research Site
-
Kunming, 중국, 650118
- 모병
- Research Site
-
Lanzhou, 중국, 730000
- 모병
- Research Site
-
Linhai, 중국, 317000
- 모병
- Research Site
-
Linyi, 중국, 276001
- 모병
- Research Site
-
Nanjing, 중국, 210009
- 모병
- Research Site
-
Nanning, 중국, 530021
- 모병
- Research Site
-
Nanning, 중국, 530000
- 모병
- Research Site
-
Shanghai, 중국, 200032
- 모병
- Research Site
-
Shanghai, 중국, 200030
- 모병
- Research Site
-
Shanghai, 중국, 200433
- 모병
- Research Site
-
Shenyang, 중국, 110022
- 모병
- Research Site
-
Taiyuan, 중국, 030000
- 모병
- Research Site
-
Tianjin, 중국, 300060
- 모병
- Research Site
-
Wenzhou, 중국, 325000
- 모병
- Research Site
-
Wuhan, 중국, 430022
- 모병
- Research Site
-
Wuhan, 중국, 430030
- 모병
- Research Site
-
Wuhan, 중국, 430010
- 모병
- Research Site
-
Wuhan, 중국, 430000
- 모병
- Research Site
-
Xi'an, 중국, 710061
- 모병
- Research Site
-
Yangzhou, 중국, 225001
- 모병
- Research Site
-
Zhengzhou, 중국, 450000
- 모병
- Research Site
-
Zhengzhou, 중국, 450008
- 모병
- Research Site
-
-
-
-
-
Chicoutimi, 캐나다, G7H 5H6
- 모병
- Research Site
-
-
British Columbia
-
Vancouver, British Columbia, 캐나다, VSZ 4E6
- 모병
- Research Site
-
-
Manitoba
-
Winnipeg, Manitoba, 캐나다, R3E 0V9
- 빼는
- Research Site
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, 캐나다, A1B 3V6
- 모병
- Research Site
-
-
Ontario
-
London, Ontario, 캐나다, N6A 4L6
- 모병
- Research Site
-
Newmarket, Ontario, 캐나다, L3Y 2P9
- 빼는
- Research Site
-
Oshawa, Ontario, 캐나다, L1G 2B9
- 모병
- Research Site
-
Toronto, Ontario, 캐나다, M4N 3M5
- 빼는
- Research Site
-
-
Quebec
-
Lévis, Quebec, 캐나다, G6V 0B8
- 모병
- Research Site
-
Montreal, Quebec, 캐나다, H4J 1C5
- 모병
- Research Site
-
Montreal, Quebec, 캐나다, H3T 1E2
- 모병
- Research Site
-
Montreal, Quebec, 캐나다, H3T 1M5
- 빼는
- Research Site
-
Rimouski, Quebec, 캐나다, G5L 5T1
- 모병
- Research Site
-
Trois-Rivières, Quebec, 캐나다, G8Z 3R9
- 모병
- Research Site
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, 캐나다, S7N 4H4
- 모병
- Research Site
-
-
-
-
-
Bangkok, 태국, 10400
- 모병
- Research Site
-
Bangkok, 태국, 10700
- 모병
- Research Site
-
Hat Yai, 태국, 90110
- 모병
- Research Site
-
Muang, 태국, 22000
- 모병
- Research Site
-
Mueang, 태국, 20000
- 모병
- Research Site
-
Mueang, 태국, 32000
- 모병
- Research Site
-
-
-
-
-
Adapazarı, 터키 (Türkiye), 54100
- 모병
- Research Site
-
Ankara, 터키 (Türkiye), 6200
- 모병
- Research Site
-
Ankara, 터키 (Türkiye), 06560
- 모병
- Research Site
-
Antalya, 터키 (Türkiye), 07070
- 모병
- Research Site
-
Diyarbakır, 터키 (Türkiye), 21280
- 모병
- Research Site
-
Istanbul, 터키 (Türkiye), 34030
- 모병
- Research Site
-
Istanbul, 터키 (Türkiye), 34890
- 모병
- Research Site
-
-
-
-
-
Olsztyn, 폴란드, 10-357
- 모병
- Research Site
-
Poznan, 폴란드, 60-569
- 모병
- Research Site
-
Przemyśl, 폴란드, 37-700
- 모병
- Research Site
-
Warsaw, 폴란드, 02-781
- 모병
- Research Site
-
Warsaw, 폴란드, 01-138
- 모병
- Research Site
-
-
-
-
-
San Juan, 푸에르토 리코, 00909
- 모병
- Research Site
-
-
-
-
-
Budapest, 헝가리, 1121
- 모병
- Research Site
-
Edelény, 헝가리, 3780
- 아직 모집하지 않음
- Research Site
-
Gyula, 헝가리, 5700
- 정지된
- Research Site
-
Gyöngyös, 헝가리, 3200
- 빼는
- Research Site
-
Gyöngyös - Mátraháza, 헝가리, 3200
- 모병
- Research Site
-
Győr, 헝가리, 9024
- 모병
- Research Site
-
Kecskemét, 헝가리, 6000
- 모병
- Research Site
-
Salgótarján, 헝가리, 3100
- 빼는
- Research Site
-
Szekszárd, 헝가리, 7100
- 모병
- Research Site
-
Szolnok, 헝가리, 5000
- 빼는
- Research Site
-
Székesfehérvár, 헝가리, 8000
- 빼는
- Research Site
-
Törökbálint, 헝가리, 2045
- 모병
- Research Site
-
-
-
-
-
Birtinya, 호주, 4575
- 빼는
- Research Site
-
Blacktown, 호주, 2148
- 빼는
- Research Site
-
Clayton, 호주, 3168
- 모병
- Research Site
-
Gosford, 호주, 2250
- 모병
- Research Site
-
Melbourne, 호주, 3000
- 빼는
- Research Site
-
South Brisbane, 호주, QL 4101
- 모병
- Research Site
-
Wodonga, 호주, 3690
- 모병
- Research Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Histologically or cytologically documented non-squamous NSCLC.
- Stage IIIB or IIIC or Stage IV metastatic NSCLC (according to Edition 8 of the AJCC staging manual) not amenable to curative surgery or definitive chemoradiation.
- Absence of sensitising EGFR mutations, and ALK and ROS1 rearrangements, and absence of documented local test result for any other known genomic alteration for which there are locally approved and available targeted first-line therapies.
- Must provide tumor sample to determine PD-L1 status, TROP2 status and other biomarkers.
- Known tumour PD-L1 expression status defined as TC ≥ 50%
- At least one lesion, not previously irradiated that qualifies as a RECIST 1.1 target lesion at baseline
- ECOG performance status of 0 or 1
- Adequate bone marrow reserve and organ function
Exclusion Criteria:
- Prior systemic therapy for advanced/metastatic NSCLC.
- Squamous cell histology, or predominantly squamous cell histology NSCLC; mixed small cell lung cancer; NSCLC histology, sarcomatoid variant.
- History of another primary malignancy within 3 years
- Active or prior documented autoimmune or inflammatory disorders (with exceptions)
- Any evidence of severe or uncontrolled disease that makes it undesirable for the participant to participate in the study or that would jeopardies compliance with the protocol.
- Has clinically significant third-space fluid retention (for example pleural effusion) and is not amenable for repeated drainage.
- History of any ILD/pneumonitis, including radiation pneumonitis (apart from radiation pneumonitis that did not require steroids), or drug-induced ILD/pneumonitis, has current or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
- Has significant pulmonary function compromise, as determined by the investigator
- Spinal cord compression, or brain metastases unless participant treated and no longer symptomatic, radiologically stable, and who require no treatment with corticosteroids or anticonvulsants.
- History of leptomeningeal carcinomatosis
- Known clinically significant corneal disease
- Active infection with TB, HBV, HCV, Hepatitis A, or known HIV infection that is not well controlled
- History of active primary immunodeficiency
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Arm 1: Datopotamab Deruxtecan in Combination With Rilvegostomig
Participants in the Datopotamab Deruxtecan (Dato-DXd) in combination with Rilvegostomig group will receive Dato-DXd plus rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle. |
Datopotamab Deruxtecan IV (intravenous)
다른 이름들:
Rilvegostomig IV (intravenous)
다른 이름들:
|
|
실험적: Arm 2: Rilvegostomig Monotherapy
Participants in the rilvegostomig monotherapy group will receive rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle. |
Rilvegostomig IV (intravenous)
다른 이름들:
|
|
활성 비교기: Arm 3: Pembrolizumab Monotherapy
Participants in the pembrolizumab group will receive pembrolizumab as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle. |
Pembrolizumab IV (intravenous)
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Progression-Free Survival (PFS) in TROP2 biomarker positive participants.
기간: Approximately 4 years
|
PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anti-cancer therapy or clinically progresses prior to RECIST 1.1 progression, in the following population: • TROP2 biomarker positive population The measure of interest is the HR of PFS. PFS by investigator will be reported as a sensitivity analysis. |
Approximately 4 years
|
|
Overall Survival (OS) in TROP2 biomarker positive participants.
기간: Approximately 6 years
|
OS is defined as the time from randomisation until the date of death due to any cause. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anti-cancer therapy, in the following population: • TROP2 biomarker positive population The measure of interest is the HR of OS. |
Approximately 6 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Progression-Free Survival (PFS) in the FAS population.
기간: Approximately 4 years
|
PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anti cancer therapy or clinically progresses prior to RECIST 1.1 progression, in the following population: • FAS population The measure of interest is the HR of PFS. PFS by investigator will be reported as a sensitivity analysis. |
Approximately 4 years
|
|
Overall Survival (OS) in the FAS population.
기간: Approximately 6 years
|
OS is defined as the time from randomisation until the date of death due to any cause. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anti-cancer therapy, in the following population: • FAS population The measure of interest is the HR of OS. |
Approximately 6 years
|
|
Assessment of Objective Response Rate (ORR) by BICR in TROP2 biomarker positive and FAS populations
기간: Approximately 4 years
|
ORR is defined as the proportion of participants who have a CR or PR, as determined by BICR per RECIST 1.1. The analyses will include all randomised participants, as randomised, with measurable disease at baseline, in the following populations:
The measure of interest is the difference of the ORR. ORR by investigator will be reported as a sensitivity analysis. |
Approximately 4 years
|
|
Assessment of Duration of Response (DoR) by BICR in TROP2 biomarker positive and FAS populations
기간: Approximately 4 years
|
DoR is defined as the time from the date of first documented response until date of documented progression per RECIST 1.1, as assessed by BICR or death due to any cause. The analyses will include all randomised participants who have a response, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anti cancer therapy or clinically progresses prior to RECIST 1.1 progression, in the following populations:
|
Approximately 4 years
|
|
Participant-reported lung cancer symptoms of NSCLC and participant-reported GHS/QOL in participants treated with Dato-DXd in combination with rilvegostomig relative to pembrolizumab.
기간: Approximately 6 years
|
Time to deterioration in: pulmonary symptoms (dyspnoea, cough, and chest pain) as measured by the NSCLC-SAQ, in overall lung cancer symptoms as measured by the NSCLC-SAQ, and in GHS/QoL as measured by the GHS/QoL scale from EORTC IL172. Time to deterioration is defined as the time from randomisation until the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold. The analyses will include all randomised participants, in the following populations:
|
Approximately 6 years
|
|
Participant-reported physical functioning in participants treated with Dato DXd in combination with rilvegostomig relative to pembrolizumab.
기간: Approximately 6 years
|
Time to deterioration in physical functioning as measured by PROMIS Physical Function short form 8c. Time to deterioration is defined as the time from randomisation until the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold. The analyses will include all randomised participants, in the following populations:
|
Approximately 6 years
|
|
Pharmacokinetics (PK)
기간: Approximately 6 years
|
Concentration of rilvegostomig, Dato-DXd, total anti TROP2 antibody, and MAAA 1181a (payload deruxtecan) in plasma or serum and PK parameters (peak and trough concentrations). |
Approximately 6 years
|
|
Immunogenicity
기간: Approximately 6 years
|
Presence of ADA for Dato-DXd and rilvegostomig (confirmatory results, titres and neutralising antibodies for confirmed positive samples). |
Approximately 6 years
|
|
Second Progression-Free Survival (PFS2).
기간: Approximately 6 years
|
PFS2 is defined as the time from randomisation to the earliest of the progression events (following the initial progression), subsequent to first subsequent therapy, or death. Progression event includes radiological (RECIST 1.1) or clinical disease progression. The date of second progression will be recorded by the investigator in the eCRF and defined according to local standard practice. The analyses will include all randomised participants, as randomised, regardless of whether the participant withdraws from subsequent therapy and regardless of missed visits, in the following populations:
|
Approximately 6 years
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Safety of Dato-DXd in combination with rilvegostomig and rilvegostomig monotherapy as compared with pembrolizumab.
기간: Approximately 6 years
|
Safety and tolerability will be evaluated in terms of AEs (graded by CTCAE Version 5.0). |
Approximately 6 years
|
공동 작업자 및 조사자
스폰서
협력자
수사관
- 수석 연구원: Suresh S. Ramalingam, MD, Emory University, Atlanta, Georgia, United States of America.
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- D7632C00001
- 2023-505077-32-00 (레지스트리 식별자: CTIS (EU))
- 2023 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.
All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD 공유 기간
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles.
For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD 공유 액세스 기준
When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool .
Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .